-
Bayer completed its acquisition of Monsanto with sales of EUR 9,481 million in the second quarter
Time of Update: 2021-02-27
Recently, Bayer reported second quarter 2018 results, during which the Group's sales increased by 8.5% (adjusted for exchange rate and portfolio) to EUR 9,481 million.
's health consumer goods business continued to decline sales of self-care products (health consumer goods) fell 1.4 per cent (adjusted for exchange rates and portfolio) to EUR 1,413 million.
-
Shangrong Healthcare's failed expansion lost its share price by 83.1 billion yuan, shrinking by 1.8 billion yuan
Time of Update: 2021-02-27
, according to the announcement, on April 4 this year, Shangrong Medical issued a plan for the 2018 public offering of convertible corporate bonds, saying that the company intends to issue convertible bonds, raising a total of not more than 900 million yuan.
-
All over the "ignition" Kangmei Pharmaceuticals half a year to throw more than 3 billion
Time of Update: 2021-02-27
On July 27th, Kangmei Pharmaceuticals, a leading Chinese medicine and beverage company, announced that, after consideration by the first interim shareholders' meeting in 2018, it had approved bills on
-
Ali Health has teamed up with a number of chain pharmacies to test the new retail of water medicine
Time of Update: 2021-02-27
August 20, Ali Health and Rookie Network announced that in Hangzhou, the first 24-hour online purchase of medicine 30 minutes on-line delivery service, no hiccups at night, within 1 hour of delivery.
-
East A gum quarterly report: net profit of 363 million, up 5.13% YoY
Time of Update: 2021-02-27
At the Xipu Conference held on August 13 this year, the 2018 "China Pharmaceutical Brand List Value List" was announced, with Dong'a gum taking the top spot and achieving its fourth consecutive crown since 2015, further consolidating the position of high-end nourishing health brands.
-
Ali pharmaceutical ecosystem gradually become a pharmacy's way of survival where to find
Time of Update: 2021-02-27
As the name implies, that is, leading enterprises to integrate the ability, advantages, resources and so on of all parties inside and outside the industry, in a certain range to form a mutually dependent, interdependent, symbiotic ecosystem, a virtuous circle, in order to achieve strategic objectives more quickly.
-
China Resources Medicine "eats" stomach-churning tablets
Time of Update: 2021-02-27
"Daily Economic News" reporter learned that after the completion of the capital increase, China Resources Pharmaceutical Holdings will hold a 51% stake in Jiang zhong group, thereby indirectly controlling jiang chinese medicine has issued shares of 43.03 percent.
-
Connbey rebuked the heavy gold stake Jia and biological good chess or stink chess
Time of Update: 2021-02-27
However, jiayu bio in the next 3 years the most likely to be listed clinical Phase III products (GB221, GB242, GB222), similar research and development competition is very fierce, competitors.
addition, another important factor in Connbel's investment in Jia and Bio is the clinical progression of its competitive PD-1 products.
-
Jiangzhong's acquisition of Sanghai Pharmaceuticals and Jisheng Pharmaceuticals' commitment to China Resources is only one step
Time of Update: 2021-02-27
Jiang Traditional Chinese Medicine will soon be included in the "China Resources Map follow-up to June 2 Jiangsao Pharmaceuticals issued "on the company's actual controller to change the prompt announcement" shows that China Resources Pharmaceutical Holdings intends to increase capital and purchase part of Jiangxi Jiang zhong pharmaceutical (Group) Co., Ltd. shares in the combination of the acquisition of Jiang zhong group not less than 51% of the shares.
-
Huaren Pharmaceuticals' proposed acquisition of Korean medicine and cosmetics marriage will have a "spark"?
Time of Update: 2021-02-27
On the evening of October 17th, Huaren Pharmaceuticals, which had earlier announced that it would acquire a well-known cosmetics company in China, finally lifted the mystery of the target, which was acquired by Han post cosmetics Co., Ltd.
-
Huada Gene's 100 billion-dollar market capitalization pharmaceutical company "collapse" is now only 29.6 billion
Time of Update: 2021-02-27
July 14th, Huada Gene issued a clarification announcement in the media, responding to questions about non-invasional prenatal genetic testing technology and whether there was exaggerated propaganda.
-
Fosun Pharma's net profit decreased by 13.44% in the first three quarters
Time of Update: 2021-02-27
Fosun Pharma explained the decline in net profit in its third-quarter report, saying it was mainly affected by higher investment in innovative research and development and business layout, losses at some participating companies and higher interest expense.
-
HNA investment to terminate major asset restructuring core medical assets listed and then stranded
Time of Update: 2021-02-27
On the evening of October 30, HNA Investment announced that the major asset restructuring plan involving 100% equity in Xinsheng Medical and 70% stake in Cihang Hospital had been terminated due to the lack of completion conditions and timing, and faced greater uncertainty.
-
North China Pharmaceuticals reported a 254.32% year-on-year increase in net profit for the third quarter
Time of Update: 2021-02-27
On October 17, North China Pharmaceuticals released its third-quarter report, reporting that the company's operating income for the January-September period was 7 billion yuan, and the net profit attr
-
The world's market capitalization of more than a trillion dollars Apple layout medical speed up
Time of Update: 2021-02-27
Apple shares were trading at $207.39 in the early hours of August 3, Beijing time, with a market capitalisation of $101.678 billion.
-
Step Pharmaceutical semi-annual report released the pace of transformation and innovation accelerated
Time of Update: 2021-02-27
Recently, Step Pharmaceuticals issued an announcement. According to the announcement, the company achieved operating income of RMB5,748 million, down 0.06% from a year earlier, and net profit attribut
-
Connbey's first three-quarter results exceeded last year's full-year stake in the company increased to 4.38 percent
Time of Update: 2021-02-27
For The first three quarters of this year to achieve a substantial increase in revenue and stable growth in net profit, the company's chairman Hu Jiqiang said, mainly due to the promotion and implementation of large-brand large-variety projects, at the same time, launched in February this year, science and technology innovation-driven development projects, both to enhance the competitiveness of the company's existing products, but also for the company's future business development laid the foundation.
-
One heart into a retail chain pharmaceutical industry leader Chairman is optimistic about the big health
Time of Update: 2021-02-27
Yunnan listed company Yunnan Hongxiang One Heart Tang Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as: One Heart Hall) recently because of three things in the listed company's pharmaceuti
-
Affected by Hurricane Maria, Haizheng Pharmaceuticals is back out of stock
Time of Update: 2021-02-27
in late May 2018, Hanyu Pharmaceuticals received notification from Pfizer that its Puerto Rico plant had been severely damaged by Hurricane Maria late last year, resulting in a degree of supply constraints for Refinan finished products in the Chinese market.
-
Medical industry "veteran" Yangzijiang Pharmaceuticals New Bureau
Time of Update: 2021-02-27
According to Yao Zhongqing, executive vice president of the Institute of Traditional Chinese Medicine of Yangzijiang Pharmaceutical Group, the current cost of research and development of single varieties of innovative Chinese medicine drugs needs to be invested at least 50 million yuan to 100 million yuan, and the effective ingredient innovation drugs need at least 200 million yuan.
